Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as "synthetic lethality". Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016.
Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.
Keywords: PARP inhibitors; Synthetic lethality; cancer therapy; drug resistance; signaling pathways; targeted therapy.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.